title: [The role of FDG-PET-CT in the evaluation of primary systemic therapy in breast cancer: links between metabolic and pathological remission].
abstract: BACKGROUND
  FDG-PET-CT is highly sensitive in detection of viable tumour tissue, giving an importance for that in oncological diagnostics.
  
  
  OBJECTIVE
  The authors analysed retrospectively the relationship between metabolic response and changes in Ki-67, a proliferation marker.
  
  
  METHODS
  Staging FDG-PET-CT scans (before and after therapy) SUVs (Standardized Uptake Value), and morphological changes in the primary tumour and axillary lymph node region were evaluated in 30 patients with breast cancer. Calculated ΔSUV were compared with Ki-67 proliferation marker (measured in biopsies and surgical specimens).
  
  
  RESULTS
  The decrease of SUV and size were significant in the primary tumour and the axillary lymph node region. Decrease of Ki-67 was significant. Significant correlation was found between Ki-67 and SUV before therapy, initial Ki-67 and ΔSUV, and ΔKi-67 and ΔSUV.
  
  
  CONCLUSIONS
  The metabolic changes were more sensitive in the measurement of the therapeutic response than morphological remission, and they correlated well with the pathological response, in not standardized clinical conditions even.
authors.affiliation: Semmelweis Egyetem Doktori Iskola Budapest. timi.tokes@gmail.com
authors.forename: Tímea
authors.initials: T
authors.lastname: Tőkés
authors.forename: Krisztián
authors.initials: K
authors.lastname: Somlai
authors.forename: Borbála
authors.initials: B
authors.lastname: Székely
authors.forename: Janina
authors.initials: J
authors.lastname: Kulka
authors.forename: Gyöngyvér
authors.initials: G
authors.lastname: Szentmártoni
authors.forename: László
authors.initials: L
authors.lastname: Torgyík
authors.forename: Hajna
authors.initials: H
authors.lastname: Galgóczy
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Lengyel
authors.forename: Tamás
authors.initials: T
authors.lastname: Györke
authors.forename: Magdolna
authors.initials: M
authors.lastname: Dank
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001365:Axilla; D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D049109:Cell Proliferation; D003287:Contrast Media / Q000378:metabolism; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism; D008198:Lymph Nodes / Q000000981:diagnostic imaging / Q000473:pathology*; D008207:Lymphatic Metastasis; D008875:Middle Aged; D064847:Multimodal Imaging / Q000379:methods; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D012074:Remission Induction; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D003287:Contrast Media; D019394:Ki-67 Antigen; D019788:Fluorodeoxyglucose F18